Bristol-Myers Squibb (NYSE:BMY) - Aktienkurs, Nachrichten und Analyse

BMY Aktienübersicht

Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte.

Über das Unternehmen

BMY grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	5/6

Belohnungen

69.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 44.73% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Hat einen hohen Schuldenstand

Die Dividende von 5.88% ist durch die Erträge nicht gut gedeckt

Community Narratives

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

US$51.69

5.0% undervalued

-1.32%

Revenue growth p.a.

23 days ago

Bristol-Myers Squibb Company Wettbewerber

Zoetis

NYSE:ZTS

US$83.1b

Pfizer

NYSE:PFE

US$163.7b

Merck

NYSE:MRK

US$287.9b

Johnson & Johnson

NYSE:JNJ

US$381.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Bristol-Myers Squibb
Historische Aktienkurse
Aktueller Aktienkurs	US$49.11
52-Wochen-Hoch	US$63.41
52-Wochen-Tief	US$39.35
Beta	0.44
11 Monat Veränderung	19.20%
3 Monate Veränderung	11.54%
1 Jahr Veränderung	-20.98%
33 Jahre Veränderung	-28.32%
5 Jahre Veränderung	2.61%
Veränderung seit IPO	2,198.38%

Aktuelle Nachrichten und Updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

BMY: Might Be Approaching A Bottom In 2024

Jan 23

Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Jan 16

Aktionärsrenditen

	BMY	US Pharmaceuticals	US Markt
7D	4.8%	7.9%	4.5%
1Y	-21.0%	15.4%	21.7%

Rendite im Vergleich zur Industrie: BMY unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 17.2% erzielte.

Rendite vs. Markt: BMY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.3 erzielte.

Preisvolatilität

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: BMY hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: BMYDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Produkte für die Bereiche Hämatologie, Onkologie, Herz-Kreislauf, Immunologie, Fibrose und neurowissenschaftliche Erkrankungen an. Zu den Produkten des Unternehmens gehören Eliquis zur Verringerung des Risikos eines Schlaganfalls/einer systemischen Embolie bei nicht-valvulärem Vorhofflimmern und zur Behandlung von TVT/PE; Opdivo für verschiedene Krebsindikationen, darunter Blasen-, Blut-, Darmkrebs, Kopf- und Halskrebs, RCC, HCC, Lungenkrebs, Melanom, MPM, Magen- und Speiseröhrenkrebs; Pomalyst/Imnovid zur Behandlung des multiplen Myeloms; Orencia zur Behandlung von aktiver rheumatoider Arthritis und Psoriasis-Arthritis; und Sprycel zur Behandlung von Philadelphia-Chromosom-positiver chronisch-myeloischer Leukämie.

Bristol-Myers Squibb Company's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Bristol-Myers Squibb im Vergleich zum Marktanteil des Unternehmens?
BMY grundlegende Statistiken
Marktanteil	US$98.15b
Gewinn(TTM)	-US$6.54b
Umsatz(TTM)	US$46.51b

2.1x

Kurs-Umsatz-Verhältnis

-15.2x

Kurs-Gewinn-Verhältnis

Ist BMY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BMY Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$46.51b
Kosten der Einnahmen	US$11.08b
Bruttogewinn	US$35.43b
Sonstige Ausgaben	US$41.97b
Umsatz	-US$6.54b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Oct 31, 2024

Gewinn per Aktie (EPS)	-3.23
Bruttomarge	76.18%
Nettogewinnspanne	-14.06%
Schulden/Eigenkapital-Verhältnis	306.9%

Wie hat sich BMY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

4.9%

Aktuelle Dividendenrendite

-74%

Ausschüttungsquote

BMY Aktienübersicht

Belohnungen

Risikoanalyse

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

Bristol-Myers Squibb Company Wettbewerber

NYSE:ZTS

US$83.1b

NYSE:PFE

US$163.7b

NYSE:MRK

US$287.9b

NYSE:JNJ

US$381.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Fourth quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Bristol-Myers Squibb Company Announces Management Changes

Erträge & Einnahmen